Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H released its earnings results on Apr 29, 2025. The company reported HK$1.229 earnings per share for the quarter, beating the consensus estimate of HK$0.603 by HK$0.625.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H overvalued?

According to Wall Street analysts Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H pay dividends?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H pays a Annually dividend of HK$0.436 which represents an annual dividend yield of 0.27%. See more information on Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H dividends here

What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H’s EPS estimate?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H have?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H has 219,900,000 shares outstanding.

What happened to Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H’s price movement after its last earnings report?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H reported an EPS of HK$1.229 in its last earnings report, beating expectations of HK$0.603. Following the earnings report the stock price went down -1.783%.

Which hedge fund is a major shareholder of Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H?

Currently, no hedge funds are holding shares in HK:0874

Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Smart Score

Neutral

Fundamentals

Return on Equity

7.22%

Trailing 12-Months

Asset Growth

1.37%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.